Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lynk Pharma Closes C1 Round with $28 Million for Oncology and Autoimmune Drugs

publication date: May 31, 2023

Lynk Pharma of Hangzhou raised $28 million in a Series C1 financing to advance its portfolio of first-in-class and best-in-class small molecule candidates for oncology and autoimmune diseases. The company is developing highly selective second-gen and tissue-restricted third-gen JAK inhibitors while exploring novel targets for drug discovery. Lynk has four Phase II clinical trials underway in China and the US for four indications, some of which are nearly ready to begin Phase III trials. Its clinical stage assets address needs in psoriasis, ulcerative colitis, rheumatoid arthritis, myelofibrosis and IBD. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital